Cargando…

Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug

The depth and versatility of siRNA technologies enable their use in disease targets that are undruggable by small molecules or that seek to achieve a refined turn-off of the genes for any therapeutic area. Major extracellular barriers are enzymatic degradation of siRNAs by serum endonucleases and RN...

Descripción completa

Detalles Bibliográficos
Autores principales: de Brito e Cunha, Danielle, Frederico, Ana Beatriz Teixeira, Azamor, Tamiris, Melgaço, Juliana Gil, da Costa Neves, Patricia Cristina, Bom, Ana Paula Dinis Ano, Tilli, Tatiana Martins, Missailidis, Sotiris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146980/
https://www.ncbi.nlm.nih.gov/pubmed/35631401
http://dx.doi.org/10.3390/ph15050575
_version_ 1784716695588306944
author de Brito e Cunha, Danielle
Frederico, Ana Beatriz Teixeira
Azamor, Tamiris
Melgaço, Juliana Gil
da Costa Neves, Patricia Cristina
Bom, Ana Paula Dinis Ano
Tilli, Tatiana Martins
Missailidis, Sotiris
author_facet de Brito e Cunha, Danielle
Frederico, Ana Beatriz Teixeira
Azamor, Tamiris
Melgaço, Juliana Gil
da Costa Neves, Patricia Cristina
Bom, Ana Paula Dinis Ano
Tilli, Tatiana Martins
Missailidis, Sotiris
author_sort de Brito e Cunha, Danielle
collection PubMed
description The depth and versatility of siRNA technologies enable their use in disease targets that are undruggable by small molecules or that seek to achieve a refined turn-off of the genes for any therapeutic area. Major extracellular barriers are enzymatic degradation of siRNAs by serum endonucleases and RNAases, renal clearance of the siRNA delivery system, the impermeability of biological membranes for siRNA, activation of the immune system, plasma protein sequestration, and capillary endothelium crossing. To overcome the intrinsic difficulties of the use of siRNA molecules, therapeutic applications require nanometric delivery carriers aiming to protect double-strands and deliver molecules to target cells. This review discusses the history of siRNAs, siRNA design, and delivery strategies, with a focus on progress made regarding siRNA molecules in clinical trials and how siRNA has become a valuable asset for biopharmaceutical companies.
format Online
Article
Text
id pubmed-9146980
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91469802022-05-29 Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug de Brito e Cunha, Danielle Frederico, Ana Beatriz Teixeira Azamor, Tamiris Melgaço, Juliana Gil da Costa Neves, Patricia Cristina Bom, Ana Paula Dinis Ano Tilli, Tatiana Martins Missailidis, Sotiris Pharmaceuticals (Basel) Review The depth and versatility of siRNA technologies enable their use in disease targets that are undruggable by small molecules or that seek to achieve a refined turn-off of the genes for any therapeutic area. Major extracellular barriers are enzymatic degradation of siRNAs by serum endonucleases and RNAases, renal clearance of the siRNA delivery system, the impermeability of biological membranes for siRNA, activation of the immune system, plasma protein sequestration, and capillary endothelium crossing. To overcome the intrinsic difficulties of the use of siRNA molecules, therapeutic applications require nanometric delivery carriers aiming to protect double-strands and deliver molecules to target cells. This review discusses the history of siRNAs, siRNA design, and delivery strategies, with a focus on progress made regarding siRNA molecules in clinical trials and how siRNA has become a valuable asset for biopharmaceutical companies. MDPI 2022-05-05 /pmc/articles/PMC9146980/ /pubmed/35631401 http://dx.doi.org/10.3390/ph15050575 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
de Brito e Cunha, Danielle
Frederico, Ana Beatriz Teixeira
Azamor, Tamiris
Melgaço, Juliana Gil
da Costa Neves, Patricia Cristina
Bom, Ana Paula Dinis Ano
Tilli, Tatiana Martins
Missailidis, Sotiris
Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug
title Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug
title_full Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug
title_fullStr Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug
title_full_unstemmed Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug
title_short Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug
title_sort biotechnological evolution of sirna molecules: from bench tool to the refined drug
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146980/
https://www.ncbi.nlm.nih.gov/pubmed/35631401
http://dx.doi.org/10.3390/ph15050575
work_keys_str_mv AT debritoecunhadanielle biotechnologicalevolutionofsirnamoleculesfrombenchtooltotherefineddrug
AT fredericoanabeatrizteixeira biotechnologicalevolutionofsirnamoleculesfrombenchtooltotherefineddrug
AT azamortamiris biotechnologicalevolutionofsirnamoleculesfrombenchtooltotherefineddrug
AT melgacojulianagil biotechnologicalevolutionofsirnamoleculesfrombenchtooltotherefineddrug
AT dacostanevespatriciacristina biotechnologicalevolutionofsirnamoleculesfrombenchtooltotherefineddrug
AT bomanapauladinisano biotechnologicalevolutionofsirnamoleculesfrombenchtooltotherefineddrug
AT tillitatianamartins biotechnologicalevolutionofsirnamoleculesfrombenchtooltotherefineddrug
AT missailidissotiris biotechnologicalevolutionofsirnamoleculesfrombenchtooltotherefineddrug